Milan Wouters

Mr. Milan Wouters

Pharmaceutical Sciences, University of Antwerp, Antwerp, Flanders, Belgium
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in mSphere
Verified
Journal Article
Open access
LMLaurence Van Moll
Laurence Van Moll
Milan WoutersMilan Wouters
Milan Wouters
JSJeroen De Smet
Jeroen De Smet
LVLinda De Vooght
Linda De Vooght
PDPeter Delputte
Peter Delputte
PCPaul Cos
Paul Cos
As effector molecules of the innate immune system, antimicrobial peptides (AMPs) have gathered substantial interest as a potential future generation of antibiotics. Here, we demonstrate the anti- Pseudomonas activity and lipopolysaccharide (LPS)-binding ability of HC1 and HC10, two cecropin peptides from the black soldier fly ( Hermetia Illucens ). Both peptides are active against a wide range of Pseudomonas aeruginosa strains, including drug-resistant clinical isolates. Moreover, HC1 and HC10 can bind to lipid A, the toxic center of LPS and reduce the LPS-induced nitric oxide and cytokine production in murine macrophage cells. This suggests that the peptide-LPS binding can also lower the strong inflammatory response associated with P. aeruginosa infections. As the activity of AMPs is often influenced by the presence of salts, we studied the LPS-binding activity of HC1 and HC10 in physiological salt concentrations, revealing a strong decrease in activity. Our research confirmed the early potential of HC1 and HC10 as starting points for anti- Pseudomonas drugs, as well as the need for structural or formulation optimization before further preclinical development can be considered. IMPORTANCE: The high mortality and morbidity associated with Pseudomonas aeruginosa infections remain an ongoing challenge in clinical practice that requires urgent action. P. aeruginosa mostly infects immunocompromised individuals, and its prevalence is especially high in urgent care hospital settings. Lipopolysaccharides (LPSs) are outer membrane structures that are responsible for inducing the innate immune cascade upon infection. P. aeruginosa LPS can cause local excessive inflammation, or spread systemically throughout the body, leading to multi-organ failure and septic shock. As antimicrobial resistance rates in P. aeruginosa infections are rising, the research and development of new antimicrobial agents remain indispensable. Especially, antimicrobials that can both kill the bacteria themselves and neutralize their toxins are of great interest in P. aeruginosa research to develop as the next generation of drugs.

Verified
Journal Article
Open access
PDF file
Milan WoutersMilan Wouters
Milan Wouters
LMLaurence Van Moll
Laurence Van Moll
LVLinda De Vooght
Linda De Vooght
ECEmilia Choinska
Emilia Choinska
JIJoanna Idaszek
Joanna Idaszek
PCPaul Cos
Paul Cos
Ventilator-associated pneumonia (VAP) remains one of the most common hospital-acquired infections (HAI). Considering the complicated diagnosis and the lack of effective treatment, prophylactic measures are suggested as the new standard to prevent the disease. Although VAP often manifests a polymicrobial nature, Pseudomonas aeruginosa remains one of the pathogens associated with the highest morbidity and mortality rates within these mechanically ventilated patients. In this paper, we report on the development of an antibacterial hydrogel coating using the polymyxin B (PMB) peptide to prevent bacterial adhesion to the polymeric substrate. We fully characterized the properties of the coating using atomic force microscopy (AFM), scanning electron microscopy (SEM), wettability analyses and Fourier-transform infrared (FTIR) and Raman spectroscopy. Furthermore, several biological assays confirmed the antibacterial and anti-biofilm effect of the tubing for at least 8 days against P. aeruginosa. On top of that, the produced coating is compliant with the requirements regarding cytocompatibility stated in the ISO (International Organization for Standardization) 10993 guidelines and an extended release of PMB over a period of at least 42 days was detected. In conclusion, this study serves as a foundation for peptide-releasing hydrogel formulas in the prevention of VAP.

24 February 2026 in ACS Infectious Diseases
Verified
Journal Article
Open access
Milan WoutersMilan Wouters
Milan Wouters
LMLaurence Van Moll
Laurence Van Moll
EDEmine Derin
Emine Derin
SLSara Van Looy
Sara Van Looy
LVLinda De Vooght
Linda De Vooght
PCPaul Cos
Paul Cos
The alarming rise of antimicrobial resistance and the declining efficacy of conventional antibiotics emphasize the need for preventive strategies. Within the setting of device-associated infections, antimicrobial peptides (AMPs) have been extensively studied as antimicrobial candidates, owing to their broad-spectrum activity and structural versatility, enabling integration into functional surface coatings. This review provides a comprehensive overview of AMP-based prophylactic approaches, with a particular focus on coatings for medical devices prone to biofilm formation, such as endotracheal tubes, catheters and implants. While surface immobilization of peptides can be accomplished through comparatively straightforward methodologies, the field has progressed toward sophisticated matrix-based systems that enhance stability, biocompatibility and controlled functionality. Yet, despite extensive in vitro and small-scale in vivo studies, clinical translation remains very limited and constrained by several hurdles including regulatory ambiguity and production costs. Overall, this work aims to provide an up-to-date overview of the AMP-based technologies in infection prevention research.